

Table S1. Model parameters.

	Parameter	Symbol	Value (95% CI)	Equation	Ref.
Modeling individual viremia trajectories	Uninfected target cells	x	A/γ (initial)	2	[1]
	Infected target cells	y	0 (initial)	2	[2]
	Free viral particles	v	1 (initial)	2	[2]
	Clearing immune response	z	1°S: 0.347 (0.285,0.548) 2°S: 0.411(0.248,0.594) 2°DHF: 0.380 (0.0298,0.526) (initial)	2	[2]
	Daily production of target cells	A	1.4×10^6	2	[3]
	Death rate target cells	γ	0.14	2	[1]
	Infection rate	β	1°S: 1.72 (1.50,1.98) 2°S: 2.30 (2.14,2.50) 2°DHF: 2.82 (2.58,3.23) ($\times 10^{-10}$)	2	[2]
	Death rate infected target cells	δ	0.14	2	[1]
	Removal rate infected cells	α	0.001	2	[2]
	Viral particle production rate	ω	1×10^4	2	[4]
Infectiousness calculations	Viral particle clearance rate	κ	1°S: 3.48 () 2°S: 5.29 () 2°DHF: 6.07 ()	2	[2]
	Growth rate immune response	η	1°S: 1.29×10^{-5} (7.96×10^{-7} , 1.09×10^{-3}) 2°S: 2.95×10^{-5} (7.36×10^{-7} , 3.95×10^{-3}) 2°DHF: 2.71×10^{-6} (5.01×10^{-7} , 0.224)	2	[2]
	Viremia (\log_{10} cDNA copies/mL)	V	-	3-6	
	Logistic intercept	β_0	A: -11.50 (-17.59,-4.16) Pre-sym S: -3.09 (-4.24,-2.01) Post-sym S: -6.37 (-7.12,-5.62)	3	[5]
	Slope coefficient	β_I	A: 2.16 (0.92, 3.42) Pre-sym S: 0.60 (0.43,0.77) Post-sym S: 0.88 (0.77, 0.98)	3	[5]
Population seroprofile calculation	Age	a		7-8	
	Proportion pre-exposed to i serotypes at age a	$e_i(a)$		7-8	
	Proportion cross-immune after exposure with i serotypes at age a	$r_i(a)$		7	
	Duration cross-immune period	σ^{-I}	2 years	1,7,13	[6]
	Proportion of the population in each age group	$p(a)$		8	
	Proportion of population pre-exposed to i serotypes	E_i		8-10	
	Proportion of population cross-immune after pre-	R_i		1,13	

	exposure to i serotypes			
Meta-analysis of (A+IS):AS ratios				
Disease outcome calculation	Asymptomatic to symptomatic ratio given pre-exposure to i serotypes	θ_i	9.2%	9 [5]
	Inapparent to apparent ratio given pre-exposure to i serotypes	ζ_i	1°: 0.82 (0.81,0.84) 2°: 0.76 (0.74,0.78) >2°:0.86 (0.63,0.97)	10 [7]
	Location and time-specific force of infection	λ_j		
Contribution of each infection class to force of infection	Infection prevalence hosts	X		11-13
	Probability that a susceptible host becomes infected upon a bite of an infectious vector	b	Cancels out	1,11
	Ratio of vectors to hosts	m	Cancels out	1,11
	Bites per vector lifetime	a/g	4	1,11-12
	Infection prevalence vectors	Y		
	Extrinsic incubation period	n	Cancels out	1,11
	Probability that a susceptible vector becomes infected upon biting an infectious host given infectious class A or S	$c_{A \text{ or } S}$		11-13
	Infectious period	t^I	5	

References

1. Gonzalez-Mejia ME, Doseff AI. Regulation of monocytes and macrophages cell fate. *Front Biosci.* 2009;14: 2413-2431.
2. Clapham HE, Tricou V, Van Vinh Chau N, Simmons CP, Ferguson NM. Within-host viral dynamics of dengue serotype 1 infection. *J R Soc Interface.* 2014;11: 10.1098/rsif.2014.0094.
3. iGPnotebook. White cell count. <http://www.gpnotebook.co.uk> (accessed 10 October 2013)
4. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. *J Virol.* 2003;77: 3929-3938.
5. Duong V, Lambrechts L, Paul RE, Ly S, Lay RS, Long KC, et al. Asymptomatic humans transmit dengue virus to mosquitoes. *Proc Natl Acad Sci U S A.* 2015;112: 14688-14693.
6. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. *J R Soc Interface.* 2013;10: 20130414.
7. Clapham HE, Cummings DA, Johansson MA. Immune status alters the probability of apparent illness due to dengue virus infection: Evidence from a pooled analysis across multiple cohort and cluster studies. *PLoS Negl Trop Dis.* 2017;11: e0005926.